SCHEMBL902376

SCHEMBL902376

Oc1c(Cc2ccc(F)c(C(F)(F)F)c2)c(C2CCC2)nc2ccnn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 2/20 0.39
GRM2 Q14416 1/20 0.35
EPHX1 P07099 1/20 0.34
CETP P11597 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
JAK2 O60674 2/20 0.33
JAK1 P23458 2/20 0.33
TYK2 P29597 2/20 0.33
JAK3 P52333 2/20 0.33
NR3C2 P08235 1/20 0.33
P2RX7 Q99572 3/20 0.33
AR P10275 1/20 0.33
TRPV1 Q8NER1 1/20 0.32
GPR52 Q9Y2T5 1/20 0.32
ADAMTS4 O75173 1/20 0.32
MMP3 P08254 1/20 0.32
MMP13 P45452 1/20 0.32
DRD4 P21917 1/20 0.32
PTPN7 P35236 1/20 0.31
DUSP3 P51452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902690 0.96 PDE2A (0.36) PDE2AGRM2EPHX1TRPM8JAK2
SCHEMBL902644 0.89 PDE2A (0.35) PDE2ACETP
SCHEMBL902461 0.88 PDE2A (0.39) PDE2AJAK2JAK1TYK2JAK3
SCHEMBL901755 0.86 MAPKAPK2 (0.39) PDE2A
SCHEMBL15274722 0.86 SLC6A2 (0.34) PDE2ACETPDRD4
SCHEMBL902240 0.84 CCR2 (0.35) PDE2A
SCHEMBL902442 0.83 CHEK1 (0.34) PDE2A
SCHEMBL902664 0.83 PDE2A (0.38) PDE2ACETPGPR52
SCHEMBL901602 0.82 CETP (0.42) CETP
SCHEMBL902593 0.82 CCR2 (0.41) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 PDE2A 2387/4885GRM2 799/4885EPHX1 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.